Ultrasound contrast agents
This article was originally published in The Gray Sheet
Executive Summary
Imavist contrast agent, developed jointly by Alliance Pharmaceutical and Schering AG, will enter a favorable reimbursement environment following FDA approval, the firms note. In July, CMS created new APCs defining ultrasound contrast agents as drugs and making them eligible for outpatient prospective "pass-through" payments covering 95% of their average wholesale cost, Alliance explains. The company has submitted the documentation requested by FDA in its August 2000 "approvable" letter and expects to launch the product by year-end
You may also be interested in...
Alliance Touts Imagent Synthetic Heart Imaging Agent As Easier To Store
Alliance Pharmaceutical Corp. will launch its Imagent ultrasound heart imaging agent at the American Society of Echocardiography meeting in Orlando June 9-12
California Court’s Inaction On TiO2 Prop 65 First Amendment Case Breeds New Lawsuits
The Personal Care Products Council seeks to stem the rising tide of titanium dioxide Proposition 65 lawsuits, requesting that a California court prohibit the state’s Attorney General and private enforcers from filing and/or prosecuting new suits against cosmetics companies failing to warn about potential TiO2 exposure.